<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are a poorly understood group of disorders caused by one or more genetic aberrations in the bone marrow-derived cell line responsible for hematopoiesis </plain></SENT>
<SENT sid="1" pm="."><plain>Recent advances in genetic medicine have offered new insights into the epigenesis as well as the prognosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, but have not resulted in new or improved curative treatment options </plain></SENT>
<SENT sid="2" pm="."><plain>Bone marrow transplantation, introduced before the advent of genetic medicine, is still the only potential cure </plain></SENT>
<SENT sid="3" pm="."><plain>Advances in other medical and pharmaceutical areas have broadened the scope of supportive care and disease-modifying therapies, and treating physicians now have a broad range of disease management options depending on a patient's likely prognosis </plain></SENT>
<SENT sid="4" pm="."><plain>There is now clear evidence that appropriate supportive care and therapeutic intervention can improve progression-free and overall survival of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
</text></document>